Detection and isolation of circulating myeloma cells for a minimally invasive blood test
Official title: Detection and Isolation of Circulating Myeloma Cells: Toward a Minimally-Invasive CLIA-Certified Diagnostic for Multiple Myeloma
Funded at Cellsbin, INC. · NIH-11409627 · Data updated 2026-11-12
A new blood-based test aims to detect and isolate rare myeloma cells from a simple blood draw to help monitor and guide treatment.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cellsbin, INC. NIH-funded |
| Lab location | 1 site (Branford, UNITED STATES) |
| Project start | September 18, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,045,925 |
| NIH project number | 1R44CA314758-01 |
| Project ID | NIH-11409627 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with suspected or diagnosed multiple myeloma who require monitoring or confirmation of disease status.
✕Less likely to help
Patients without myeloma or without need for circulating tumor cell assessment may not benefit.
What this research studies
This project builds a blood test that can find and separate circulating myeloma plasma cells with high sensitivity. It uses the CB-Insight platform, combining imaging, microfluidics, and machine learning to identify and capture viable cells from blood. The goal is to provide a minimally invasive alternative to bone marrow biopsies and enable real-time disease tracking and better therapeutic decisions.
Why it matters
Potential benefit: If successful, patients could receive more precise monitoring and faster, less invasive assessments of disease status.
How similar studies have gone: Prior methods struggle with sensitivity; this approach aims to improve detection by two orders of magnitude over flow cytometry, with some prior methods showing progress in circulating cell detection.
Where this research is happening
-
Cellsbin, INC.
Branford, United States Active
Researchers
- Principal investigator: Kabiri, Ali — Cellsbin, INC.
- Study coordinator: Kabiri, Ali
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.